Radioisotopes for the palliation of metastatic bone cancer: a systematic review (Q28253672)

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

Bone markers in the management of metastatic bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

The pathophysiology of cancer-induced bone pain: current understanding

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

Strontium-89 chloride for pain palliation in prostatic skeletal malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

Endo-osseous isotope therapy of malignant skeletal disease (author's transl)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

Treatment of metastatic bone pain with strontium-89

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

89Strontium in bone metastases from hormone resistant prostate cancer: palliation effect and biochemical changes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

Strontium-89 for symptomatic metastatic prostate cancer to bone: recommendations for hospice patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

Strontium-89 chloride (Metastron) for palliative treatment of bony metastases. The University of Minnesota experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

Strontium-89 chloride in the treatment of bone metastases from breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

[Treatment of metastatic bone pain with repeated doses of strontium-89 in patients with prostate neoplasm]

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

Palliation of bone metastases in prostate cancer. Hemibody irradiation or strontium-89?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

Modification of the effects of continuous low dose rate irradiation by concurrent chemotherapy infusion

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

Radiosensitization with low-dose carboplatin enhances pain palliation in radioisotope therapy with strontium-89

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

Strontium and samarium therapy for bone metastases from prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

Preliminary results of the use of Re-186-HEDP for palliation of pain in patients with metastatic bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

Palliative analgesic effect of Re-186 HEDP in various cancer patients with bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

Rhenium-188 HEDP to treat painful bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

Rhenium-188-HEDP in the palliative treatment of bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970206-0

7 January 2021

10.1016/S1470-2045(05)70206-0

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

15925817

1 reference

Consolidated OpenCitations Corpus – April 2017